text size: T | T
Back to Snapshot
Company Description

Contact Info

Lilly Corporate Center

Indianapolis, IN 46285

United States

Phone: 317-276-2000


Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical and animal health products. The company’s animal health business, operating through its Elanco division, develops, manufactures, and markets products for both food animals and companion animals. The company’s products are sold in approximately 125 countries. Segments Human Pharmaceutical Products segment Endocrinology Products The company’s endocrinology products include Humalog, Humalog Mix 75/25, and Humalog Mix 50/50, insulin analogs for the treatment of diabetes; Humulin, human insulin of recombinant DNA origin for the treatment of diabetes; Trajenta, for the treatment of type 2 diabetes; Jentadueto, a combination tablet of linagliptin (Trajenta) and metformin hydrochloride for use in the treatment of type 2 diabetes; Jardiance, for the treatment of type 2 diabetes (approved in the United States (U.S.), Europe, and Japan in 2014); Trulicity, for the treatment of type 2 diabetes (approved in the U.S. and Europe in 2014, and Japan in 2015); Glyxambi, a combination tablet of linagliptin and empagliflozin (Jardiance) for the treatment of type 2 diabetes (approved in the U.S. in January 2015); and Synjardy, a combination tablet of empagliflozin and metformin hydrochloride for the treatment of type 2 diabetes (approved in the U.S. and Europe in 2015). The company’s endocrinology products also comprise Forteo, for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture and for glucocorticoid-induced osteoporosis in men and postmenopausal women; Evista, for the prevention and treatment of osteoporosis in postmenopausal women and for the reduction of the risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer; Humatrope, for the treatment of human growth hormone deficiency and certain pediatric growth conditions; and Axiron, a topical solution of testosterone, applied by underarm applicator, for replacement therapy in men for certain conditions associated with a deficiency or absence of testosterone. The company also offers Basaglar (insulin glargine injection), a long-acting human insulin analog for the treatment of diabetes (launched in Japan in 2015 and in Europe in 2015 under the trade name Abasaglar). Basaglar was also approved in the U.S. in 2015; under an agreement settling patent litigation with Sanofi-Aventis U.S. LLC (Sanofi) regarding Sanofi's insulin glargine product, the company would have the ability to launch Basaglar in the U.S. on December 15, 2016. Under the terms of the agreement, Sanofi has granted the company a royalty-bearing license so it can manufacture and sell Basaglar in the Kwikpen device worldwide. Neuroscience Products The company’s neuroscience products include Cymbalta, for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain due to chronic low back pain or chronic pain due to osteoarthritis; Zyprexa, for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; Strattera, for the treatment of attention-deficit hyperactivity disorder; Prozac, for the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and Amyvid, a radioactive diagnostic agent for positron emission tomography imaging of beta-amyloid neuritic plaques in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. Oncology Products The company’s oncology products comprise Alimta, for the first-line treatment, in combination with another agent, of advanced non-small cell lung cancer (NSCLC) for patients with non-squamous cell histology; for the second-line treatment of advanced non-squamous NSCLC; as monotherapy for the maintenance treatment of advanced non-squamous NSCLC in patients whose disease has not progressed immediately following chemotherapy treatment; and in combination with another agen


The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

LLY* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LLY*.
View Industry Companies

Industry Analysis


Industry Average

Valuation LLY* Industry Range
Price/Earnings 37.5x
Price/Sales 4.3x
Price/Book 5.8x
Price/Cash Flow 38.9x
TEV/Sales 3.9x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ELI LILLY & CO, please visit www.lilly.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.